Patents Assigned to Icosagen Cell Factory Oü
-
Patent number: 11685936Abstract: This disclosure provides methods and landing pad constructs for generation of parental cell lines suitable for targeted integration. A method is provided by the parental cell line development; this is, the introduction of binding sites of BPV1 E2 protein to landing pad vectors so that expressed BPV1 E2 protein could locate the vector to transcriptionally active region in the genome. Cells with high expression level of reporter genes are selected for the next stage and will be used in the development of cell lines expressing another recombinant protein by recombination mediated cassette exchange (RMCE). Landing pad constructs include recombination target sites for site-specific recombinases, and therefore, it could be replaced with gene-of-interest expression construct containing the same set of recombination target sites. This yields the generation of producer cell lines with less effort compared to traditional cell line development by random integration.Type: GrantFiled: October 17, 2019Date of Patent: June 27, 2023Assignee: Icosagen Cell Factory OÜInventors: Kadri Õunap, Eva-Maria Tombak, Mart Toots, Madis Jakobson, Mart Ustav, Jr., Kerttu Murumets, Urve Toots, Andres Männik, Mart Ustav, Sr.
-
Patent number: 11000529Abstract: Methods for treating high risk HPV infection by inhibiting one or more phases of HPV replication cycle with antiviral compounds are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.Type: GrantFiled: September 12, 2019Date of Patent: May 11, 2021Assignee: Icosagen Cell Factory OÜInventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
-
Patent number: 10954545Abstract: A U2OS-based model system using luciferase reporters to monitor the genome replication of alpha and beta HPVs is provided. A modified U2OS cell line is disclosed that expresses Firefly luciferase to measure toxicity of the screened compounds. In addition, provided are HPV18, HPV 16 and HPV5 marker genomes that express Renilla luciferase under the control of viral promoters used to measure changes in the viral copy number. This ready-to-use model system is capable of being used in high-throughput screens to identify compounds inhibiting initial amplification and stable maintenance as well as vegetative phase of various HPV subtypes.Type: GrantFiled: April 11, 2016Date of Patent: March 23, 2021Assignee: Icosagen Cell Factory OÜInventors: Mart Ustav, Ene Ustav, Andres Männik, Mart Toots, Mart Ustav, Jr., Andres Tover
-
Publication number: 20200123576Abstract: This disclosure provides methods and landing pad constructs for generation of parental cell lines suitable for targeted integration. A method is provided by the parental cell line development; this is, the introduction of binding sites of BPV1 E2 protein to landing pad vectors so that expressed BPV1 E2 protein could locate the vector to transcriptionally active region in the genome. Cells with high expression level of reporter genes are selected for the next stage and will be used in the development of cell lines expressing another recombinant protein by recombination mediated cassette exchange (RMCE). Landing pad constructs include recombination target sites for site-specific recombinases, and therefore, it could be replaced with gene-of-interest expression construct containing the same set of recombination target sites. This yields the generation of producer cell lines with less effort compared to traditional cell line development by random integration.Type: ApplicationFiled: October 17, 2019Publication date: April 23, 2020Applicant: Icosagen Cell Factory OÜInventors: Kadri ÕUNAP, Eva-Maria TOMBAK, Mart TOOTS, Madis JAKOBSON, Mart USTAV, Jr., Kerttu MURUMETS, Urve TOOTS, Andres MÄNNIK, Mart USTAV, Sr.
-
Publication number: 20200046730Abstract: Methods for treating high risk HPV infection by inhibiting one or more phases of HPV replication cycle with antiviral compounds are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.Type: ApplicationFiled: September 12, 2019Publication date: February 13, 2020Applicant: Icosagen Cell Factory OÜInventors: Mart USTAV, SR., Ene USTAV, Andres MÄNNIK, Mart TOOTS, Andres TOVER
-
Patent number: 10543218Abstract: Novel antiviral compounds for inhibiting one or more phases of HPV replication cycle are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.Type: GrantFiled: May 11, 2016Date of Patent: January 28, 2020Assignee: Icosagen Cell Factory OÜInventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
-
Publication number: 20180273611Abstract: This invention provides a method and a kit for rapid and robust development monoclonal antibodies. The method does not require hybrid technologies nor does it require single cell manipulations. The method allows elimination of cross-target antibodies.Type: ApplicationFiled: September 30, 2016Publication date: September 27, 2018Applicant: Icosagen Cell Factory OÜInventors: Gaily KIVI, Kaupo TEESALU, Jüri PARIK, Mart USTAV, Andres MÄNNIK
-
Publication number: 20180155756Abstract: A U2OS-based model system using luciferase reporters to monitor the genome replication of alpha and beta HPVs is provided. A modified U2OS cell line is disclosed that expresses Firefly luciferase to measure toxicity of the screened compounds. In addition, provided are HPV18, HPV 16 and HPV5 marker genomes that express Renilla luciferase under the control of viral promoters used to measure changes in the viral copy number. This ready-to-use model system is capable of being used in high-throughput screens to identify compounds inhibiting initial amplification and stable maintenance as well as vegetative phase of various HPV subtypes.Type: ApplicationFiled: April 11, 2016Publication date: June 7, 2018Applicant: Icosagen Cell Factory OÜInventors: Mart USTAV, Ene USTAV, Andres MÄNNIK, Mart TOOTS, Mart USTAV, JR., Andres TOVER
-
Publication number: 20180133228Abstract: Novel antiviral compounds for inhibiting one or more phases of HPV replication cycle are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.Type: ApplicationFiled: May 11, 2016Publication date: May 17, 2018Applicant: Icosagen Cell Factory OÜInventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
-
Patent number: 8377653Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).Type: GrantFiled: July 7, 2010Date of Patent: February 19, 2013Assignee: Icosagen Cell Factory OüInventors: Toomas Silla, Ingrid Tagen, Anne Kalling, Radi Tegova, Mart Ustav, Tiiu Mandel, Urve Toots, Andres Tover, Aare Abroi, Ene Ustav, Jelizaveta Geimanen, Kadri Janikson